Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market trends in scleritis treatment are evolving as a result of advancements in medical research, increased awareness, and a deeper understanding of the underlying causes of this inflammatory eye condition. These trends signify a comprehensive approach to managing scleritis and improving the quality of life for individuals affected by this potentially sight-threatening disorder.
Among important tendencies in the scleritis field are the application and developing investigations related to inflammation-reducing medicine. The investigation for efficacy is going, on, via novel medications, such as biologics, and target immunomodulators, in suppressing the inflammatory response for scleritis. Tailored treatment path for the patients serves as a basis for this development that enhances effectiveness and efficiency of treatments.
A budding trend is seen in the market for biosimilars coming up to replace existing biologic treatments used in treating scleritis. Biosimilars present a less expensive alternative to the original biologics making them more available therefore less barriers for patients to access these advanced therapies. The 'build-to-rent' (BTR) trend, which connects with efforts to address cost and management challenges of scleritis, is a significant factor.
These days, personalization has become a norm in scleritis management as there is an increasing trend of individual treatment approach. Identifying the particular subtype of scleritis, the likeliness for the success of the treatment, and the individual needs of the patient is essential in the modern era. It has a personalized approach that is a blend of maximizing the effectiveness and minimizing the observed side effects.
Consultative care programs that envision the participation of ophthalmologists, rheumatologists, and other medical specialists are creating strides in scleritis management. Multidisciplinary collaboration guarantees a wider acquisition of the determinants and the system itself, and as a result more comprehensive treatment strategies.
Teleophthalmology is advanced which is responsible for integrating telecommunication so that the remote eye consultations can easily be held. Virtual visit allows the ophthalmologists to check on and give care in an obvious and timely manner and the same way for those who are not geographically and ease of access to health care facilities. Trends inclination in accuracy of diagnosis leads to widening of patient care offer.
The market is witnessing an increased focus on genetic and molecular research to better understand the underlying mechanisms of scleritis. Investigating genetic predispositions and identifying molecular markers may lead to targeted therapies and a deeper understanding of the factors contributing to the development and progression of scleritis.
Despite these advancements, challenges persist in ensuring timely diagnosis and access to specialists for scleritis patients. Limited awareness among healthcare providers and delays in referral to ophthalmologists or rheumatologists may hinder early intervention. Addressing these challenges is crucial for optimizing outcomes in scleritis management.
Scleritis Market Highlights:
Scleritis Market Overview
Scleritis Market Size was valued at USD 2.9 Billion in 2023. The Global Scleritis industry is projected to grow from USD 3.08 Billion in 2024 to USD 4.99 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period (2024 - 2032).
Scleritis is a medical condition that causes painful inflammation of sclera (white part of the eye). In some severe cases, the disease is reported to cause loss of vision, i.e., by affecting episclera and sclera. Thus, its timely diagnosis and treatment are necessary against scleritis. Focal redness or violaceous discoloration, scleral thickening, late scleral, and scleral necrosis are some of the prominent symptoms associated with the disease.
It is established that more than 50% of scleritis cases are associated with autoimmune disease, including rheumatoid arthritis. The prevalence of rheumatoid arthritis is increasing and, thus, the susceptible scleritis patient population. It is suggestive that the prevalence of rheumatoid arthritis was about 0.5–1.0% within regional boundaries of North America and Northern Europe. This scleritis market is indicating a positive market growth during the forecast period, 2022–2030.
Moreover, factors such as the growing aging population and increasing per capita healthcare expenditure boost the market growth. However, lack of awareness in the middle-income countries and the absence of targeted treatment is estimated to restraint the market growth during the forecast period.
Scleritis Market Segmentation
Scleritis market has been segmented into type, diagnostic test & treatment, end-user, and region.
The scleritis market, based on type, has been segmented into anterior scleritis and posterior scleritis. The anterior scleritis segment is further segmented into diffuse scleritis, nodular scleritis, and necrotizing scleritis.
The scleritis global market, by diagnostic test & treatment, has been divided into diagnostic tests and treatment. The diagnostic test market is further segmented into ultrasonography, complete blood count, biopsy, others.
The treatment segment is sub-divided into medication and surgery. The medication segment is further classified into corticosteroid, nonsteroidal anti-inflammatory drugs, and immunosuppressive drugs. The corticosteroid segment is sub-segmented into difluprednate, prednisolone, and others. The nonsteroidal anti-inflammatory drugs segment is further classified into aspirin, ibuprofen, and others. The immunosuppressive drugs segment is sub-segmented into methotrexate, mycophenolate, and others.
The end-user segment has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.
Scleritis Market Key Players
- Amgen
- Amneal Pharmaceuticals LLC
- Baxter International Inc.
- Boehringer Ingelheim
- Fresenius Kabi USA, LLC
- Jubilant Cadista Pharmaceuticals Inc.
- Mylan Pharmaceuticals Inc.
- Novartis Pharmaceuticals
- Perrigo Company
- Roxane Laboratories, Inc.
- Sandoz Inc.
- Shanghai Henlius Biotech
- Teva Pharmaceuticals USA, Inc.
- West-Ward Pharmaceuticals
- Zydus Pharmaceuticals (USA) Inc.
Regional Market Summary
Geographically, the Americas is projected to lead the scleritis market. This can be attributed due to the presence of well-developed healthcare infrastructure and the increasing prevalence of scleritis within the Americas.
Europe is expected to hold the second-largest share of the scleritis market owing to government support and the presence of developed countries such as the UK, Germany, and France within the region.
The scleritis market in Asia-Pacific is segmented into China, Japan, India, Australia, South Korea, and the rest of the Asia-Pacific. The region is estimated to grow with the highest CAGR. High prevalence of scleritis, growing geriatric population, and increasing penetration of market players boost the regional market. In India, the mean age of scleritis patients is estimated to be about 55. This susceptible age group is expanding, which is growing the treatment-seeking patient pool.
The Middle East & Africa is anticipated to hold the least share of the market owing to the presence of poor economies, stringent government regulations, and low per capita income in Africa. Within the region, the Middle East is projected to lead the market owing to developed healthcare infrastructure and the presence of economies such as Saudi Arabia, Kuwait, and Dubai.
Scleritis Market, by Type
- Anterior Scleritis
- Diffuse Scleritis
- Nodular Scleritis
- Necrotizing Scleritis
- Posterior Scleritis
Scleritis Market, by Diagnostic Test & Treatment
- Diagnostic Test
- Ultrasonography
- Complete Blood Count
- Biopsy
- Others
- Treatment
- Medication
- Corticosteroid
- Difluprednate
- Prednisolone
- Others
- Nonsteroidal Anti-Inflammatory Drugs
- Aspirin
- Ibuprofen
- Others
- Immunosuppressive Drugs
- Methotrexate
- Mycophenolate
- Others
- Corticosteroid
- Surgery
- Medication
Scleritis Market, by End User
- Hospitals & Clinics
- Diagnostic Centers
- Academic & Research Organizations
Scleritis Market, by Region
- Americas
- North America
- US
- Canada
- South America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Intended Audience
- Pharmaceutical companies
- Medical devices companies
- Contract research organizations
- Contract manufacturing organizations
- Research and development organization
- Academics and research institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
